Finerenone Routine Care Findings
In this small, single-center routine-care cohort, finerenone use was associated with lower proteinuria alongside an early eGFR decline and modest early potassium increases; the design cannot determine causation or long-term cardiovascular benefit.
> Research explainer: This briefing examines verified primary research published 54 days before the briefing date. It is not a same-day research update and does not provide medical advice.
Evidence
This research explainer examines a study published on 2026-07-01. The investigators conducted a single-center retrospective cohort study at a tertiary medical center in Al-Ahsa, Saudi Arabia, using routine-care records from adults who received finerenone between January 2023 and December 2024. Of 75 screened patients, 67 met the inclusion criteria for diabetic kidney disease or a urine protein-to-creatinine ratio (uPCR) above 0.3 mg/mg. Follow-up measurements of uPCR, estimated glomerular filtration rate (eGFR), serum creatinine, and potassium were collected for up to 12 months after the first documented finerenone prescription. [pmid:42384643]
The cohort had substantial cardiovascular comorbidity: 56.8% had heart failure and 40.3% had coronary artery disease. These baseline figures make the study relevant to a Heart & Lungs briefing, while the measured outcomes themselves were kidney laboratory measures and potassium rather than cardiovascular events or pulmonary outcomes. [pmid:42384643]
For uPCR, the authors reported a significant effect of time and a mean reduction of 0.464 mg/mg at six months (95% CI, -0.895 to -0.034; P=0.027). The estimated eGFR slope after finerenone initiation was -1.08 mL/min/1.73 m² per month (95% CI, -1.74 to -0.41; P=0.002), approximately -12.9 mL/min/1.73 m² per year. The authors characterized this as an early decline requiring cautious interpretation. [pmid:42384643]
Potassium increased at the first three follow-up readings by 0.209, 0.256, and 0.286 mmol/L, respectively, then plateaued at later readings. The study reported a favorable overall safety profile, but its abstract does not provide a comparative event analysis against an untreated group. [pmid:42384643]
Analysis — Cardiorenal Interpretation
The results describe a pattern observed after finerenone initiation in one routine-care cohort: lower measured proteinuria at six months, an early negative eGFR slope, and modest early potassium increases that later plateaued. The co-occurrence of heart failure and coronary artery disease in more than half and about two-fifths of participants, respectively, places the cohort in a clinically complex cardiorenal setting. However, those diagnoses are baseline characteristics, not outcomes shown to improve or worsen after treatment in this study. [pmid:42384643]
The proteinuria finding is statistically reported, but it should be interpreted as an association over follow-up rather than proof that finerenone produced the change. A retrospective, single-group cohort can reflect patient selection, concurrent treatments, changes in care over time, or incomplete measurement patterns. The reported eGFR decline also cannot be assigned a single explanation from these data. The authors explicitly advised caution in interpreting the early decline, and the available follow-up was limited to 12 months. [pmid:42384643]
For Heart & Lungs readers, the key boundary is between comorbidity context and outcome evidence. The study documents that many participants entered treatment with heart failure or coronary artery disease, but it does not establish a reduction in heart-failure events, coronary events, mortality, hospitalization, or pulmonary outcomes. Its contribution is a localized description of laboratory trajectories and potassium observations during finerenone use in adults with diabetic kidney disease. [pmid:42384643]
Limitations
This was a single-center retrospective cohort of 67 eligible participants without a stated untreated comparison group. Therefore, the observed changes cannot establish causation or isolate finerenone from other clinical factors. The setting was one Saudi Arabian tertiary medical center, which limits how readily the findings generalize to other settings and populations. [pmid:42384643]
The study followed measurements for up to 12 months, so it did not establish long-term cardiorenal outcomes. It also excluded people receiving dialysis, those with kidney transplantation or an expected transplant within 12 months, baseline potassium of at least 4.9 mmol/L, HbA1c of at least 12%, or systolic blood pressure of at least 170 mmHg. The findings may not apply to those excluded groups. [pmid:42384643]
Finally, this source supports a research explainer, not medical advice, a prediction, or a patient-specific conclusion. It provides no basis for inferring that the observed laboratory associations translate into long-term cardiovascular benefit in an individual or in other populations. [pmid:42384643]